FLORHAM PARK, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that its novel phospholipid radiotherapeutic conjugate, iopofosine I 131, demonstrated a pathological response with complete clonal clearance in a relapsed/refractory Waldenstrom's macroglobulinemia (WM) patient with CNS involvement, also known as Bing- ...

Table of Contents 6 The accompanying notes are an integral part of these condensed consolidated financial statements. The accompanying notes are an integral part of these condensed consolidated financial statements. CELLECTAR BIOSCIENCES, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) The condensed consolidated financial statements have been prepared by Cellectar Biosciences, Inc. in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) f ...

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors James Caruso - CEO Chad Kolean - CFO Shane Lea - CCO Andrei Shustov - SVP, Medical Conference Call Participants Jonathan Aschoff - ROTH MKM Jeffrey Jones - Oppenheimer Ahu Demir - Ladenburg Jason McCarthy - Maxim Group Operator Good morning, and welcome to Cellectar Biosciences Third Quarter 2023 Update Call. Today's conference is being recorded. At thi ...

2022 Reverse Stock Split Equity Distribution Agreement Common Stock Warrants The Company maintains the 2021 Stock Incentive Plan (the "2021 Plan"). All outstanding awards under the 2015 Stock Incentive Plan (the "2015 Plan") remained in effect according to the terms of the 2015 Plan. Any shares that are currently available under the 2015 Plan and any shares underlying 2015 Plan awards which are forfeited, cancelled, reacquired by the Company or otherwise terminated are added to the number of shares availabl ...

In August 2016, the University of Wisconsin Carbone Cancer Center (UWCCC) was awarded a five-year Specialized Programs of Research Excellence (SPORE) grant of $12,000,000 from the NCI and the National Institute of Dental and Craniofacial Research to improve treatments and outcomes for head and neck cancer (HNC) patients. HNC is the sixth most common cancer across the world with approximately 56,000 new patients diagnosed every year in the U.S. As a key component of this grant, the UWCCC researchers complete ...

| --- | --- | --- | |---------------------------|-------|-------| | | | | | | | | | | | | | | | | | CELLECTAR BIOSCIENCES (3) | | | | | | | | lopofosine l 131 | | | | | | | | | | | Iopofosine I 131: Lead Candidate First-in-class Phospholipid Ether Radiotherapeutic to Target Cancer 5 Iopofosine I 131: WM Phase 2a Response Rates Forward Looking Statements and Disclaimers This presentation contains forward-looking statements. Such statements are valid only as of today and we disclaim any obligation to update t ...

B-cell Non-Hodgkin's Lymphoma (BCNHL) represents cancers of the lymphatic system. The lymphoma may be indolent or aggressive and circulate in the blood or form tumors in lymph nodes. According to the American Cancer Society, the estimated 2023 US incidence of BCNHL was 68,468 cases. Nine types of B-cell lymphomas include CLL, SLL, MCL, MZL, and the most common lymphoma, DLBCL. According to a report dated June 2019 by Global Data Research Group, the BCNHL market was valued at $7.2 billion for 2022, with a fo ...

| --- | --- | --- | |----------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Corporate | | | | | | | | | | | | Presentation | | | | November 2022 | | | | NASDAQ: CLRB | | | Forward-Looking Statements and Disclaimers This presentation contains forward-looking statements. Such statements are valid only as of today and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that m ...

Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [mark one] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 1-36598 CELLECTAR BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) ...

Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [mark one] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 1-36598 CELLECTAR BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) DELAW ...